GOSS

Gossamer Bio Inc

Oct 14 • 12:18PM ET

2.32

-0.12 -4.92 %

Healthcare • Biotechnology • USA • NASD

Peers: BLUE CRSP SRPT FATE NTLA ADAP EDIT QURE BMRN VYGR

| Held by: VTI IWM VXF IWO SCHA VTWO IWC VFMO ITOT PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	20.22%	Shs Outstand	227.32M	Perf Week	-7.20%
Market Cap	527.52M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	0.06%	Shs Float	181.40M	Perf Month	-27.04%
Enterprise Value	517.43M	PEG	-	EPS next Q	-0.19	Inst Own	61.59%	Short Float	15.10%	Perf Quarter	39.76%
Income	-138.74M	P/S	13.11	EPS this Y	-170.00%	Inst Trans	3.47%	Short Ratio	7.13	Perf Half Y	185.40%
Sales	40.24M	P/B	-	EPS next Y	24.44%	ROA	-45.17%	Short Interest	27.40M	Perf YTD	156.47%
Book/sh	-0.20	P/C	2.48	EPS next 5Y	3.09%	ROE	-783.37%	52W High	3.60 -35.56%	Perf Year	135.84%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	56.92% 40.29%	ROIC	-89.03%	52W Low	0.66 250.61%	Perf 3Y	-80.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.26%	Volatility	8.25% 8.22%	Perf 5Y	-82.37%
Dividend TTM	-	EV/Sales	12.86	EPS Y/Y TTM	-57.23%	Oper. Margin	-361.91%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.40	Sales Y/Y TTM	-58.02%	Profit Margin	-344.81%	RSI (14)	42.23	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.40	EPS Q/Q	-181.59%	SMA20	-13.67%	Beta	1.87	Target Price	9.00
Payout	-	Debt/Eq	-	Sales Q/Q	-88.01%	SMA50	-7.93%	Rel Volume	0.49	Prev Close	2.44
Employees	145	LT Debt/Eq	-	Earnings	Aug 05 AMC	SMA200	51.63%	Avg Volume	3.84M	Price	2.32
IPO	Feb 08, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.01% 112.41%	Trades		Volume	863,672	Change	-4.92%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-25	Upgrade	UBS	Neutral → Buy	$9
Jul-14-25	Initiated	Scotiabank	Sector Outperform	$11
Jun-25-24	Initiated	Oppenheimer	Outperform	$9
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30

Show Previous Ratings

Sep-25-25 07:41AM	Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital (PR Newswire) -7.02%
07:31AM	Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension (Business Wire)
Sep-23-25 07:22PM	Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress (Insider Monkey)
Sep-22-25 07:31AM	Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-11-25 01:15PM	H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects (Insider Monkey) +11.25%
03:31AM	Loading…
03:31AM	Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case (Insider Monkey)
Sep-10-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.27%
Aug-29-25 07:31AM	Gossamer Bio to Present at Upcoming Investor Conferences (Business Wire)
Aug-19-25 12:06AM	H.C. Wainwright and Leerink Partners Reiterate 'Buy' Ratings on Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Aug-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.12%
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.33%
04:53PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 07:05AM	GSK (GSK) Q2 Earnings and Revenues Beat Estimates (Zacks) +6.12%
12:46PM	Loading…
Jun-24-25 12:46PM	Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib (Insider Monkey)
Jun-16-25 07:31AM	Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH (Business Wire)
Jun-06-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.56%
May-21-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream (GlobeNewswire)
May-16-25 09:11AM	Q1 2025 Gossamer Bio Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study (Business Wire)
May-14-25 09:45AM	What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings (GuruFocus.com) -7.34%
May-12-25 04:01PM	Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 (Business Wire)
May-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:01PM	Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference (Business Wire)
May-02-25 01:21PM	Gossamer Bio: Initiating Hold As Late-Stage Data Nears Inflection (Seeking Alpha) +11.32%
Apr-16-25 09:57AM	Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? (Insider Monkey)
09:44AM	Loading…
Apr-09-25 09:44AM	Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple (Insider Monkey) +11.76%
Apr-08-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:45AM	Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch? (InsiderMonkey)
Mar-26-25 01:38PM	Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5? (InsiderMonkey) -7.81%
Mar-23-25 08:41AM	Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-13-25 05:10PM	Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +11.54%
04:06PM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.38%
Feb-03-25 07:01AM	Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-28-25 07:01AM	Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.41%
09:19AM	Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-26-24 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-21-24 12:00PM	All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy (Zacks)
Nov-15-24 09:35AM	After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks)
Nov-14-24 09:35AM	After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks) -5.59%
Nov-11-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 06:00PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-07-24 05:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-26-24 04:01PM	Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 (Business Wire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-12-24 10:53PM	GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:10PM	Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:15PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 02:35AM	Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-13-24 03:35PM	The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street (InvestorPlace)
Jun-07-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.60% -6.09%
May-14-24 04:01PM	Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference (Business Wire)
May-10-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-24 10:56PM	GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 (InvestorPlace) -6.30%
05:15PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
05:11AM	Gossamer Bio and Chiesi partner for pulmonary hypertension treatment (Pharmaceutical Technology)
04:31AM	Gossamer Bio and Chiesi link for pulmonary hypertension treatment (Pharmaceutical Technology)
May-06-24 03:17PM	Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide (Benzinga) +5.50%
08:17AM	UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (Reuters)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
07:41AM	Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment (Reuters)
07:30AM	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications (Business Wire)
May-03-24 08:02AM	Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine (Business Wire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24% +7.16%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Milligan Sandra	Director	Aug 19 '25	Buy	1.92	26,050	50,016	58,050	Aug 20 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience